Dr. Klomp completed her PhD at the University of Illinois Chicago where she developed tools to study the Src proto-oncogene. Her subsequent work has focused on understanding the role of aberrant kinase activity in KRAS mutant cancers and how to exploit this therapeutically. She is currently identifying how ERK kinase supports pancreatic cancer cell growth using a combination of transcriptomics, phosphoproteomics, engineered kinases, and functional genetic screens. Dr. Klomp has been awarded postdoctoral fellowships from the NCI (F32 and K99/R00) and American Cancer Society.
Jennifer Klomp - Google Scholar